// App-Quantinova.ai

e21680 : Phase I dose escalation study of immunoconjugate L-DOS47 in combination with pemetrexed/carboplatin in non-squamous non-small cell lung cancer (NSCLC) patients.

Researchers

Presenter

  • Afshin Dowlati

Principal Investigators

  • Chandra Prakash Belani

  • George R. Simon

  • Heman Chao

  • Sarina Anne Piha-Paul

Medical Centers

  • University Hospitals Case Medical Center, Cleveland, OH

  • Penn State Cancer Institute, Hershey, PA

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Helix BioPharma Corp, Aurora, ON, Canada

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Carboplatin

  • Pemetrexed

  • L-DOS47

  • DOS47

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • NA

Study Id's

  • NCT02309892

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved